Independent guide to finasteride. Not a pharmacy and not a telehealth company.

Finasteride studies: the key trials

By the Finasteride.com editorial team. Sources are listed at the end of the page.

Short answerFinasteride is one of the most studied hair loss drugs, with placebo-controlled trials in more than 1,500 men followed for up to five years. Larger prostate trials at the 5 mg dose (PLESS, MTOPS and PCPT) add long-term safety data from tens of thousands of men.
Where to get it

Finasteride needs a prescription. These providers issue one online.

Compare all providersNot sure? Take the 1-minute quiz

The trials at a glance

Six trials account for most of what is known about finasteride. Three tested it for hair, and three tested the higher prostate dose in older men.

TrialWho and how longDoseMain finding
Kaufman 19981,553 men aged 18 to 41, 1 to 2 years1 mg107 more hairs than placebo at 1 year, 138 at 2 years
5-year extension (2002)Same men, up to 5 years1 mgDurable improvement; placebo group kept losing hair
Piraccini 2022 (topical)458 men, 24 weeksScalp sprayHair count up 20.2 versus 6.7 with placebo
PLESS 19983,040 men with BPH, 4 years5 mgRisk of surgery and urinary retention cut by more than half
MTOPS 20033,047 men with BPH, mean 4.5 years5 mg, with or without doxazosinCombination cut progression risk by 66%
PCPT 200318,882 men aged 55 and over, 7 years5 mgFewer prostate cancers overall, more high-grade ones

All six were randomized and placebo-controlled, meaning men were assigned by chance to the drug or an inactive tablet.

The hair loss trials: Kaufman 1998 and the five-year extension

The Kaufman trials showed that finasteride 1 mg increased hair count and slowed loss, and the extension showed the benefit lasted five years. In two one-year trials, 1,553 men with thinning at the crown took finasteride 1 mg or placebo, and 1,215 continued into blinded extensions. Hair was counted in a 1-inch circle that held 876 hairs on average at the start.

The one-year difference of 107 hairs was measured against a starting count of 876, so the gap between finasteride and placebo was about 12% of the hair in the counted area.

Finasteride beat placebo on hair counts, patient and investigator ratings and photographs at one and two years, while the placebo group lost hair steadily.

The extension ran for up to four more years. The published report concluded that improvements were durable over five years and that no new safety concerns appeared. The Propecia label adds the figures: at five years, 35% of men on finasteride had a lower hair count than at the start, compared with 100% of men on placebo. See the results timeline.

The topical phase III trial

The Piraccini trial found that a finasteride scalp spray beat placebo and gave a hair count gain numerically similar to the tablet over 24 weeks. Peak blood levels of finasteride were more than 100 times lower with the spray, and blood DHT fell 34.5% versus 55.6% with the tablet. Details are on the topical finasteride page.

The prostate trials: PLESS and MTOPS

PLESS and MTOPS established finasteride 5 mg as a long-term treatment for benign prostatic hyperplasia (BPH, an enlarged prostate). In PLESS, 10% of men on placebo and 5% on finasteride needed prostate surgery over four years, and acute urinary retention occurred in 7% and 3%. In MTOPS, the risk of BPH progression fell 34% with finasteride, 39% with doxazosin and 66% with both. See finasteride for BPH.

PCPT: the prostate cancer prevention trial

PCPT found that finasteride lowered the overall rate of prostate cancer but raised the rate of high-grade tumors, which led to a label warning. Over seven years, prostate cancer was found in 18.4% of men on finasteride 5 mg and 24.4% on placebo. Cancers with a Gleason score of 8 to 10 (the most aggressive grades) were found in 1.8% versus 1.1%. The finasteride labels now carry a warning that drugs in this class may increase the risk of high-grade prostate cancer. The long-term safety page covers the FDA's 2011 communication, the later survival follow-up, and how the finding is interpreted.

The hair trials have gaps. They enrolled men aged 18 to 41 with mild to moderate loss, controlled data stop at five years, and trials of this size cannot measure rare events such as the persistent side effects reported after approval.

Common questions

What was the main finasteride hair loss study?

The two trials reported by Kaufman and colleagues in 1998, which enrolled 1,553 men and were extended to five years. They are the basis of the FDA approval.

Did the trials find that finasteride causes prostate cancer?

No. PCPT found fewer prostate cancers overall with finasteride but more high-grade ones, which is why the label carries a warning.

Are there trials of finasteride in women?

Yes. A one-year placebo-controlled trial in 137 postmenopausal women found no benefit at 1 mg. See finasteride for women.

Sources

  1. Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. Journal of the American Academy of Dermatology, 1998. PubMed 9777765
  2. Finasteride Male Pattern Hair Loss Study Group. Long-term (5-year) multinational experience with finasteride 1 mg in the treatment of men with androgenetic alopecia. European Journal of Dermatology, 2002. PubMed 11809594
  3. Organon. Propecia (finasteride) tablets 1 mg, full prescribing information and patient information. DailyMed, National Library of Medicine. DailyMed: Propecia label
  4. Piraccini BM, Blume-Peytavi U, Scarci F, et al. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. Journal of the European Academy of Dermatology and Venereology, 2022. PubMed 34634163
  5. McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. New England Journal of Medicine, 1998. PubMed 9475762
  6. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. New England Journal of Medicine, 2003. PubMed 14681504
  7. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. New England Journal of Medicine, 2003. PubMed 12824459
Compare finasteride providers